Stock ticker :
NYSE
ABT
AS OF
Jan 14, closing price
Price
$128.12
Change
-$1.50 (-1.16%)
Capitalization
$226.6b
ABT
Stock ticker :
NYSE
8 days until earnings call
Intraday data for
Jan 14, closing price
Price
$128.12
Change
-$1.50 (-1.16%)
Capitalization
$226.6b

(ABT) Stock Forecast and AI Recommendations

a manufacturer of health care products
Industry MedicalSpecialties

Abbott Laboratories (ABT) Stock Stock Prediciton and Price Targets

Stock market charts, price targets, analyst ratings and a financial calendar
a manufacturer of health care products
Industry MedicalSpecialties
A.I.dvisor published
a Summary for ABT with price predictions.
4:00 PM EST Jan 14

ABT sees MACD Histogram just turned negative

ABT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 04, 2022. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 21 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 42%.

Stock Forecast, Price, News, Quote

Current price $128.12 is below $133.78 the lowest support line found by A.I. Throughout the month of 12/14/21 - 01/14/22, the price experienced a -3% Downtrend. During the week of 01/07/22 - 01/14/22, the stock fell -5%.

Technical Analysis (Indicators)
Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 05, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on ABT as a result. In 28 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 34%.

ABT moved below its 50-day Moving Average on January 13, 2022 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 38%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in 206 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

ABT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 199 of 364 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.583) is normal, around the industry mean (9.351). P/E Ratio (31.847) is within average values for comparable stocks, (71.773). Projected Growth (PEG Ratio) (2.500) is also within normal values, averaging (4.280). Dividend Yield (0.014) settles around the average of (0.017) among similar stocks. P/S Ratio (5.426) is also within normal values, averaging (118.646).

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.

A.I.dvisor published
Abbott Laboratories Earnings Data

ABT is expected to report earnings to fall 14.29% to $1.20 per share on January 26

Abbott Laboratories ABT Stock Earnings Report
Q4'21
Est.
$1.20
Q3'21
Beat
by $0.46
Q2'21
Beat
by $0.15
Q1'21
Beat
by $0.05
Q4'20
Beat
by $0.10
The last earnings report on October 20 showed earnings per share of $1.40, beating the estimate of 94 cents. With 8.82M shares outstanding, the current market capitalization sits at 226.62B.
A.I.dvisor found
Abbott Laboratories Dividends
ABT is expected to pay dividends on February 15, 2022
Abbott Laboratories ABT Stock Dividends
A dividend of $0.47 per share will be paid with a record date of February 15, 2022, and an ex-dividend date of January 13, 2022. The last dividend of $0.45 was paid on November 15. The ex-dividend date is usually set several business days before the record date. If a stock is purchased on its ex-dividend date or after, the next dividend payment will not be received. Instead, the dividends are repossessed by to the seller. If the stocks are purchased before the ex-dividend date, the buyer will receive the dividends.
A.I.dvisor
published General Information

General Information

Profile
Fundamentals
Details
Industry Medical Specialties
Address 100 Abbott Park Road, Abbott Park, IL, 60064-6400
Phone +1 224 667-6100
Employees 107000
Web https://www.abbott.com
ABT

Select Stock attributes to show

Capitalization 227B
P/E Ratio 31.85
Risk (Beta) 0.69
Dividend Yield 0.01
Total Cash 8.944B
Total Cash/Share 5.06
Total Debt 18.5B
Total Debt/Equity 33.06
Projected Growth (PEG Ratio) 2.50
Revenue/Share (as % of the share price) 24%
Revenue 40.2B
ROE N/A
Book Value 33.8B
P/B Ratio 6.58
Cash Flow N/A
Earnings 3.570
Average Daily Volume YTD N/A
Common Shares Outstanding - Security Level 24.2B
Current Ratio 1.79
Current Revenue Per Employee 93,788.99
Dividends Per Share - Security 0.45
EBITDA 11.2B
Float N/A
Float - Current N/A
Gross Income Margin 51.61
Revenue To Assets 8.98
Shares Held By Institutions 1.323T
Shares Outstanding - Current N/A
Total Liabilities 39.2B
Total Volume MTD N/A
Value Over
Gain YTD -8.617
Group Domestic Stock Funds
Category Medical Specialties
Total Expense Ratio
Min. Initial Investment 0.00 USD
Fund Existence
Turnover
Front Load
Net Assets 0.00 USD
Manager Tenure
Group Domestic Stock Funds
Category Medical Specialties
Capitalization 226.62b USD
P/E Ratio 31.847134
Total Cash 8.94b USD
Projected Growth 2.50
Total Debt 18.50b USD
Revenue 40.23b USD
Risk (Beta) 0.69
Dividend Yield 0.01
Total Cash/Share 5.06
Total Debt/Equity 33.06
Revenue/Share 24.00USD as % of share price
Group Domestic Stock Funds
Category Medical Specialties
Net Assets 0.00 USD
Fund Existence
Turnover
Capitalization
Yield
Total Expense Ratio
Investment Style
Risk (Beta)
Group Domestic Stock Funds
Category Medical Specialties
Market Capitalization 0.00 USD
Volume 0.00 USD